Novo Nordisk (NVO.N) shares rose more than 8% in pre-market trading in the U.S. as clinical trials showed its weight loss drug Amycretin reduced body weight by 22%.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up
to date with North American business news.
Weekly Highlights